Loxo Oncology (NASDAQ:LOXO) Earns Coverage Optimism Score of 0.19
News stories about Loxo Oncology (NASDAQ:LOXO) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Loxo Oncology earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.6391677290782 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Array BioPharma To Report Financial Results For The Fourth Quart – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- Loxo Oncology, Inc. (NASDAQ:LOXO) Downgraded to Sell at BidaskClub (americanbankingnews.com)
- Nanotechnology Innovations in Ceramic Fibers, Smart Bandages, Diagnostics, Encapsulation, and Quantum Dots – Research and Markets (4-traders.com)
- This Drug Discovery Company Just Struck a $40 Million Deal with Loxo Oncology (LOXO) (biospace.com)
- BRIEF-Loxo Oncology acquires BTK inhibitor program (uk.reuters.com)
Shares of Loxo Oncology (NASDAQ LOXO) traded up 2.95% on Friday, reaching $72.92. The company’s stock had a trading volume of 164,267 shares. Loxo Oncology has a 1-year low of $17.14 and a 1-year high of $83.12. The company has a 50 day moving average of $75.53 and a 200 day moving average of $53.18. The stock’s market capitalization is $1.91 billion.
Loxo Oncology (NASDAQ:LOXO) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.20. Equities research analysts expect that Loxo Oncology will post ($4.22) earnings per share for the current fiscal year.
A number of brokerages have weighed in on LOXO. BidaskClub lowered Loxo Oncology from a “hold” rating to a “sell” rating in a report on Friday. Stifel Nicolaus restated a “buy” rating and issued a $71.00 price objective on shares of Loxo Oncology in a report on Thursday. BTIG Research restated a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a report on Thursday. Morgan Stanley restated an “overweight” rating and issued a $91.00 price objective on shares of Loxo Oncology in a report on Monday, June 19th. Finally, Zacks Investment Research upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a report on Thursday, June 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Loxo Oncology presently has a consensus rating of “Buy” and an average target price of $70.83.
COPYRIGHT VIOLATION NOTICE: “Loxo Oncology (NASDAQ:LOXO) Earns Coverage Optimism Score of 0.19” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/06/loxo-oncology-nasdaqloxo-earns-coverage-optimism-score-of-0-19.html.
In other Loxo Oncology news, Director Keith T. Flaherty sold 7,250 shares of the company’s stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $45.09, for a total value of $326,902.50. Following the sale, the director now owns 27,141 shares of the company’s stock, valued at $1,223,787.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 44.40% of the stock is currently owned by corporate insiders.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.